Targeting EGFR-dependent tumors by disrupting an ARF6-mediated sorting system

Area of Science:

• Oncology
• Cell Biology
• Molecular Biology

Background:

• Aberrant activation of epidermal growth factor receptor (EGFR) is linked to poor prognosis in various cancers.
• Targeting EGFR is a key strategy in cancer treatment, but resistance mechanisms remain a challenge.

Purpose of the Study:

• To investigate the role of protein sorting in EGFR localization and its therapeutic implications.
• To identify key molecular players in the EGFR sorting pathway.
• To develop a novel therapeutic strategy targeting EGFR trafficking.

Main Methods:

• Investigated EGFR palmitoylation by DHHC13 and its role in plasma membrane localization.
• Identified and characterized the function of ARF6 in EGFR trafficking.
• Utilized lipid-lipid interaction studies to understand EGFR-ARF6 recognition.
• Designed and tested a cell-permeable peptide (N-myristoylated GKVL-TAT) to disrupt EGFR localization.

Main Results:

• EGFR palmitoylation by DHHC13 is essential for its plasma membrane localization.
• ARF6, in its N-myristoylated and GTP-bound form, mediates EGFR transport from the Golgi to the plasma membrane.
• N-myristoylated ARF6 interacts with palmitoylated EGFR via lipid-lipid interactions.
• The peptide N-myristoylated GKVL-TAT effectively inhibited EGFR plasma membrane localization and tumor progression in EGFR-dependent tumors.

Conclusions:

• Disrupting the EGFR sorting system is a potent therapeutic strategy for EGFR-dependent tumors.
• Understanding the mechanism of palmitoylation-directed protein sorting offers new insights into cellular transport.
• N-myristoylated GKVL-TAT represents a potential therapeutic agent for managing EGFR-driven cancers.